268 related articles for article (PubMed ID: 16489007)
1. Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumors.
Skliarenko JV; Lunt SJ; Gordon ML; Vitkin A; Milosevic M; Hill RP
Cancer Res; 2006 Feb; 66(4):2074-80. PubMed ID: 16489007
[TBL] [Abstract][Full Text] [Related]
2. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.
Davis PD; Dougherty GJ; Blakey DC; Galbraith SM; Tozer GM; Holder AL; Naylor MA; Nolan J; Stratford MR; Chaplin DJ; Hill SA
Cancer Res; 2002 Dec; 62(24):7247-53. PubMed ID: 12499266
[TBL] [Abstract][Full Text] [Related]
3. Interstitial permeability and elasticity in human cervix cancer.
Milosevic M; Lunt SJ; Leung E; Skliarenko J; Shaw P; Fyles A; Hill RP
Microvasc Res; 2008 Apr; 75(3):381-90. PubMed ID: 18187164
[TBL] [Abstract][Full Text] [Related]
4. Associations between radiocurability and interstitial fluid pressure in human tumor xenografts without hypoxic tissue.
Rofstad EK; Ruud EB; Mathiesen B; Galappathi K
Clin Cancer Res; 2010 Feb; 16(3):936-45. PubMed ID: 20103667
[TBL] [Abstract][Full Text] [Related]
5. Long-term performance of interstial fluid pressure and hypoxia as prognostic factors in cervix cancer.
Fyles A; Milosevic M; Pintilie M; Syed A; Levin W; Manchul L; Hill RP
Radiother Oncol; 2006 Aug; 80(2):132-7. PubMed ID: 16920212
[TBL] [Abstract][Full Text] [Related]
6. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice.
Goto H; Yano S; Zhang H; Matsumori Y; Ogawa H; Blakey DC; Sone S
Cancer Res; 2002 Jul; 62(13):3711-5. PubMed ID: 12097279
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126.
Evelhoch JL; LoRusso PM; He Z; DelProposto Z; Polin L; Corbett TH; Langmuir P; Wheeler C; Stone A; Leadbetter J; Ryan AJ; Blakey DC; Waterton JC
Clin Cancer Res; 2004 Jun; 10(11):3650-7. PubMed ID: 15173071
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.
Blakey DC; Westwood FR; Walker M; Hughes GD; Davis PD; Ashton SE; Ryan AJ
Clin Cancer Res; 2002 Jun; 8(6):1974-83. PubMed ID: 12060643
[TBL] [Abstract][Full Text] [Related]
9. Lack of general correlation between interstitial fluid pressure and oxygen partial pressure in solid tumors.
Boucher Y; Lee I; Jain RK
Microvasc Res; 1995 Sep; 50(2):175-82. PubMed ID: 8538498
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effect of the vascular-disrupting agent ZD6126 in a murine renal cell carcinoma model.
Medinger M; Esser N; Soltau J; Lehmann KM; Konerding MA; Wolloscheck T; Ryan AJ; Drevs J
Int J Oncol; 2011 Feb; 38(2):455-64. PubMed ID: 21152862
[TBL] [Abstract][Full Text] [Related]
11. Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements.
Milosevic M; Fyles A; Hedley D; Pintilie M; Levin W; Manchul L; Hill R
Cancer Res; 2001 Sep; 61(17):6400-5. PubMed ID: 11522633
[TBL] [Abstract][Full Text] [Related]
12. Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.
Goto H; Yano S; Matsumori Y; Ogawa H; Blakey DC; Sone S
Clin Cancer Res; 2004 Nov; 10(22):7671-6. PubMed ID: 15570000
[TBL] [Abstract][Full Text] [Related]
13. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors.
Siemann DW; Rojiani AM
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):846-53. PubMed ID: 15936569
[TBL] [Abstract][Full Text] [Related]
14. Tumor angiogenesis and interstitial hypertension.
Boucher Y; Leunig M; Jain RK
Cancer Res; 1996 Sep; 56(18):4264-6. PubMed ID: 8797602
[TBL] [Abstract][Full Text] [Related]
15. Interstitial hypertension in carcinoma of uterine cervix in patients: possible correlation with tumor oxygenation and radiation response.
Roh HD; Boucher Y; Kalnicki S; Buchsbaum R; Bloomer WD; Jain RK
Cancer Res; 1991 Dec; 51(24):6695-8. PubMed ID: 1742744
[TBL] [Abstract][Full Text] [Related]
16. Time response of interstitial fluid pressure measurements in cervix cancer.
Khosravani H; Chugh B; Milosevic MF; Norwich KH
Microvasc Res; 2004 Jul; 68(1):63-70. PubMed ID: 15219421
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive magnetic resonance imaging of transport and interstitial fluid pressure in ectopic human lung tumors.
Hassid Y; Furman-Haran E; Margalit R; Eilam R; Degani H
Cancer Res; 2006 Apr; 66(8):4159-66. PubMed ID: 16618737
[TBL] [Abstract][Full Text] [Related]
18. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse.
Boucher Y; Jain RK
Cancer Res; 1992 Sep; 52(18):5110-4. PubMed ID: 1516068
[TBL] [Abstract][Full Text] [Related]
19. Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126.
Cullis ER; Kalber TL; Ashton SE; Cartwright JE; Griffiths JR; Ryan AJ; Robinson SP
Microvasc Res; 2006 Mar; 71(2):76-84. PubMed ID: 16530791
[TBL] [Abstract][Full Text] [Related]
20. Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure.
Ferretti S; Allegrini PR; O'Reilly T; Schnell C; Stumm M; Wartmann M; Wood J; McSheehy PM
Clin Cancer Res; 2005 Nov; 11(21):7773-84. PubMed ID: 16278399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
